- Home
- RNTX vs ZYXI Comparison
RNTX vs ZYXI Comparison
Compare RNTX & ZYXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNTX
- ZYXI
- Stock Information
- Founded
- RNTX 2001
- ZYXI 1996
- Country
- RNTX United States
- ZYXI United States
- Employees
- RNTX N/A
- ZYXI N/A
- Industry
- RNTX Biotechnology: Pharmaceutical Preparations
- ZYXI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- RNTX Health Care
- ZYXI Health Care
- Exchange
- RNTX Nasdaq
- ZYXI Nasdaq
- Market Cap
- RNTX 34.6M
- ZYXI 35.8M
- IPO Year
- RNTX N/A
- ZYXI N/A
- Fundamental
- Price
- RNTX $1.25
- ZYXI $0.55
- Analyst Decision
- RNTX Buy
- ZYXI Hold
- Analyst Count
- RNTX 2
- ZYXI 3
- Target Price
- RNTX $10.00
- ZYXI $3.00
- AVG Volume (30 Days)
- RNTX 2.6M
- ZYXI 5.4M
- Earning Date
- RNTX 11-14-2025
- ZYXI 11-17-2025
- Dividend Yield
- RNTX N/A
- ZYXI N/A
- EPS Growth
- RNTX N/A
- ZYXI N/A
- EPS
- RNTX N/A
- ZYXI N/A
- Revenue
- RNTX N/A
- ZYXI $108,202,000.00
- Revenue This Year
- RNTX N/A
- ZYXI N/A
- Revenue Next Year
- RNTX N/A
- ZYXI $7.07
- P/E Ratio
- RNTX N/A
- ZYXI N/A
- Revenue Growth
- RNTX N/A
- ZYXI N/A
- 52 Week Low
- RNTX $1.04
- ZYXI $0.38
- 52 Week High
- RNTX $3.50
- ZYXI $8.72
- Technical
- Relative Strength Index (RSI)
- RNTX 44.48
- ZYXI 25.34
- Support Level
- RNTX $1.15
- ZYXI $0.38
- Resistance Level
- RNTX $1.32
- ZYXI $1.20
- Average True Range (ATR)
- RNTX 0.20
- ZYXI 0.14
- MACD
- RNTX -0.04
- ZYXI -0.07
- Stochastic Oscillator
- RNTX 11.65
- ZYXI 19.82
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
About ZYXI Zynex Inc.
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company operates business as one operating segment which includes two revenue types: Devices and Supplies. Its markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.